Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)

Cryogenic preservation plays a central role in cellular therapy, long-term biological storage, regenerative medicine, and advanced manufacturing of therapeutic cell lines. This study investigates how varying cooling rates, cryoprotectant concentrations, and thaw-recovery procedures influence viability and functionality in human-derived cell samples.

The intervention consists of laboratory-controlled freeze-thaw cycles at temperatures ranging from -80 °C to -196 °C under defined standard and experimental conditions. Post-thaw evaluations include viability assays, growth kinetics, apoptotic markers, metabolic profiling, and structural assessment.

The study is non-clinical and does not involve living human subjects. All cell materials are obtained under appropriate consent or supplied as commercially available research-grade lines.

Inclusion criteria

• This study does not enroll human participants. Eligibility applies only to human-derived cell samples.
• Samples must be de-identified prior to receipt.
• Samples must demonstrate ≥90% viability at pre-freeze assessment.
• Samples must be free of contamination (bacterial, fungal, mycoplasma).
• Samples must meet chain-of-custody and biospecimen compliance requirements.

Exclusion criteria

• No human participants will be enrolled or contacted.
• Any specimen containing identifiable private information.
• Samples with inadequate quality, contamination, or compromised viability.
• Samples obtained without appropriate donor consent or de-identification certification.